Gabriele Todisco

He has been working on translational research projects in myeloid neoplasms since 2018 focusing on incorporating detailed molecular information from DNAseq and RNAseq into clinical practice. His research is aiming to improve classification and treatment of myeloid neoplasms by exploring germline and acquired mechanisms driving myeloid neoplasms development and disease progression. He is member of Italian Hematology Society and Nordic MDS Research Group.

1. Moura PL, Mortera-Blanco T, Hofman IJ, Todisco G, et al. Erythroid Differentiation Enhances RNA Mis-Splicing in SF3B1-Mutant Myelodysplastic Syndromes with Ring Sideroblasts. Cancer Res. 2024 Jan 16;84(2):211-225.
2. Todisco G, Creignou M, Bernard E, Hellström-Lindberg E, et al. Integrated genomic and transcriptomic analysis improves disease classification and risk stratification of MDS with ring sideroblasts. Clin Cancer Res. 2023 Oct 13;29(20):4256-4267
3. Cieśla M, Ngoc PCT, Muthukumar S, Todisco G, et al. m6A-driven SF3B1 translation control steers splicing to direct genome integrity and leukemogenesis. Mol Cell. 2023 Apr 6;83(7):1165-1179.e11
4. Nicola Guzzi, Sowndarya Muthukumar, Maciej Cieśla, Gabriele Todisco, et al. Pseudouridine-modified tRNA fragments repress aberrant protein synthesis and predict leukaemic progression in myelodysplastic syndrome. Nat Cell Biol. 2022 Mar;24(3):299-306.
5. Ellen M. Beauchamp, Matthew Leventhal, Elsa Bernard, Emma R Hoppe, Gabriele Todisco, et al. ZBTB33 is mutated in clonal hematopoiesis and myelodysplastic syndromes and impacts RNA splicing. Blood Cancer Discov. 2021 Sep;2(5):500-517.